ORIC® PHARMACEUTICALS ANNOUNCES ENOZERTINIB (ORIC-114) LATE-BREAKING ORAL PRESENTATIONS IN EGFR ATYPICAL AND EGFR EXON 20 NSCLC AT THE ESMO ASIA CONGRESS 2025

Reuters · 2d ago

Please log in to view news